Objectives: Hypermutable strains of Pseudomonas aeruginosa frequently emerge during chronic airways infection in cystic fibrosis (CF) patients. While the increased accumulation of mutations by hypermutable strains determines a biological cost for the colonization of secondary environments, the mutator phenotypes might confer a selective advantage under antibiotic treatment in a CF airways environment.
Introduction
Pseudomonas aeruginosa chronic airways infection is recognized as being the most important contributor to the morbidity, mortality and premature death in many cases of patients with cystic fibrosis (CF). 1 Despite intensive antibiotic treatments, P. aeruginosa infections are difficult to eradicate. 2 The antibiotic treatment may actually favour the emergence of antimicrobial drug resistance and selects pathogenic variants. 3 One of the most striking characteristics of P. aeruginosa in the lung of CF patients is the diversification of the bacterial population and the presence of multiple phenotypes, including those that are highly resistant to any chemotherapy treatment. 4 These clones can arise from a number of different mechanisms involving mutation of the chromosomal genes linked only in part to the consumption of antibiotics. 5 Such mechanisms usually involve mutations in the genes encoding drug targets or in the systems that affect drug accumulation. 6 In addition, defects in the methyl-directed mismatch repair (MMR), a post-replicative repair system that corrects errors on newly synthesized DNA strands to ensure the fidelity of chromosome replication, are present in naturally occurring strains. 7 Elevated mutation rates displayed by hypermutators are likely to benefit the organisms by increasing the frequency with which antibiotic resistance arises and enhancing the opportunity for compensatory mutations to reduce fitness costs sometimes associated with the acquisition of endogenous antibiotic resistance. 8 There is alarming evidence of naturally occurring hypermutable strains with antibiotic multiresistant phenotypes in CF patients. Hypermutable strains were detected in up to 37% of the CF patients with P. aeruginosa chronic infection in the first report, in which a strong link between hypermutation and antibiotic resistance was also observed. 9 The high prevalence of chronic infection by hypermutable P. aeruginosa strains in patients with CF and other chronic underlying respiratory diseases was confirmed in subsequent studies. 10 -14 The causal relationship between colonization by hypermutable bacteria and deterioration of lung function has not been demonstrated directly. However, recent clinical studies suggest that the presence of hypermutable strains is linked to the poorer respiratory function of CF patients compared with patients colonized by non-hypermutable bacteria. 15, 16 Given the effect of antibiotic failure on the prognosis of CF patient lung function, it is likely that colonization with hypermutable bacteria leads first to antibiotic treatment failure and consequently to lung deterioration. Furthermore, the intensive genetic adaptation process catalysed by hypermutable strains may also favour their long-term persistence in CF airways. 12 Our work investigates the response of several clonal pairs of P. aeruginosa hypermutable and wild-type CF strains to antibiotic pressure in vitro and in a murine model, and provides key results on lung pathogenicity during long-term chronic infection.
Methods

Ethics statement
Animal studies were conducted according to protocols approved by the San Raffaele Scientific Institute (Milan, Italy) Institutional Animal Care and Use Committee (IACUC) and adhered strictly to the Italian Ministry of Health guidelines for the use and care of experimental animals.
Research on the bacterial isolates from the individuals with CF was approved by the responsible physician at the CF centre at Hannover Medical School, Germany. All patients gave informed consent before sample collection. Approval for storing of biological materials was obtained by the Hannover Medical School, Germany.
Bacterial strains
A total of 12 P. aeruginosa strains of clinical origin (BT1, BT2, BST2, BST44, SG2, NN84, NN2, NN83, RP73, RP74, MF1 and MF2) obtained from sputum samples or throat swabs from CF patients were used in this study. Clinical P. aeruginosa strains were genotyped as described previously.
17 P. aeruginosa laboratory strains PAO1 18 and PAO1DmutS 19 were used in this study as reference strains. Hypermutable strains (BT1, BST44, SG2, NN84, NN83, RP74 and MF2) had been previously characterized through the determination of rifampicin resistance mutation frequencies, 9, 13 and were complemented with a wild-type copy of the MMR gene (BT1mutS + , BST44mutS
+ and PAO1DmutS/mutS + ) as described previously. 13 
Antibiotic susceptibility testing
MICs were determined for amikacin, ceftazidime, imipenem, meropenem, ciprofloxacin, piperacillin/tazobactam, ticarcillin/clavulanic acid, streptomycin and nalidixic acid. MICs were determined by the broth microdilution method in Mueller-Hinton cation-adjusted broth (MHB) according to the CLSI guidelines.
In vitro competition experiments
Competition between P. aeruginosa wild-type and hypermutable clonal strains was performed in vitro. Strains were grown overnight in tryptic soy broth, and each culture was diluted to a starting 600 nm optical density (OD 600 ) of 0.025 and subcultured for an additional 24 h into fresh medium in the presence of a competitor. Competition experiments were performed in the presence or absence of 50 mg/L streptomycin or 0.5 mg/L ciprofloxacin added to the fresh medium used for the subcultures. The starting ratios of hypermutable to wild-type were 1 : 1 and the ratio of the mixed inoculum after 24 h was determined on mediumselective tryptic soy agar (TSA) plates, taking advantage of different antibiotic resistance patterns identified within the pairs. Therefore, susceptible strains BST2 and NN2, and resistant strains BST44 (10 mg/L amikacin) and NN83 (30 mg/L amikacin) were tested in competition. For PAO1DmutS, resistance to kanamycin (250 mg/L) was used. The plating efficiency on antibiotic medium, i.e. cfu enumeration for cultures of the resistant strain, yielded the same numbers in plates with and without antibiotic. The competition index (CI) was calculated as the ratio of hypermutable to wild-type bacteria determined from TSA plates with and without antibiotic after 24 h adjusted by the input ratio (in vitro CI). 13, 20 Mouse model
The agar beads P. aeruginosa mouse model was used. 4, 21, 22 A starting amount of 5×10 9 hypermutable/wild-type bacteria, mixed at a ratio of 1 :1, was used for inclusion in the agar beads.
13 C57BL/6 male mice (Charles River; 22-24 g) were infected with 2×10 6 cfu. Competitions in the presence of antibiotic treatment were performed by adding streptomycin (0.001 mg/L) to the drinking water 8, 23 or treating mice subcutaneously once a day with ciprofloxacin (20 mg/kg). 24 Fourteen days after infection the murine lungs were excised, homogenized and plated onto TSA plates in the presence and absence of antibiotics in different indicator plates. The CI was calculated as the ratio of hypermutable to wild-type bacteria recovered from the murine lungs after 14 days from infection adjusted by the input ratio that were inoculated in each animal (in vivo CI). 13, 20 Histopathology and immunofluorescence After 14 days of infection, the lungs were removed en bloc, fixed in 10% buffered formalin for at least 24 h and embedded in paraffin. Consecutive 2 mm sections from the middle of the five lung lobes were used for the histological and immunofluorescence examination of each mouse. Sections for histological analysis were stained with haematoxylin and eosin and examined blindly. Localization of P. aeruginosa was performed in de-paraffinized lung sections by employing a rabbit antiserum specific for P. aeruginosa and Texas Red-labelled goat anti-rabbit IgG as described previously. 4, 25 Immunofluorescence images were recorded with an EM-CCD Hamamatsu C9100 camera (Hamamatsu Photonics, Hamamatsu City, Japan) mounted on an UltraVIEW Spinning Disk Confocal Microscope (Perkin Elmer, Waltham, MA, USA). Slides stained with haematoxylin and eosin were visualized with Axioplan2 (Zeiss, Jena, Germany) with AxioCam equipped with the CCD MRc5 (Zeiss).
Statistical analysis
Data were analysed for statistical significance using unpaired two-tailed non-parametric Student's t-test or x 2 . A P value of ≤0.05 was considered significant. The GraphPad statistical package was used for the statistical analysis.
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Results
Effect on antibiotic resistance of complementation of P. aeruginosa hypermutable strains with MMR genes Seven clinical P. aeruginosa hypermutable strains and their clonal pairs, previously identified and characterized from CF patients, 13 were tested for resistance to seven antibiotics (amikacin, ceftazidime, imipenem, meropenem, ciprofloxacin, piperacillin/ tazobactam and ticarcillin/clavulanic acid) routinely used in chemotherapy and two additional antibiotics (streptomycin and nalidixic acid) by measuring their MICs ( Table 1 ). The presence of endogenous resistance or development of resistance in vitro following exposure to antibiotics of hypermutable P. aeruginosa clinical strains was distinguished by complementation of hypermutable strains with the wild-type copy of MMR genes mutS, mutL or uvrD.
As shown in Table 1 , both the P. aeruginosa laboratory strain PAO1DmutS and the clinical hypermutable strains were generally more resistant to antibiotics when compared with the nonhypermutable strains. Interestingly, the complementation of the clinical P. aeruginosa hypermutable strains with the wild-type copy of the MMR genes decreased the MICs, changing the antibiotic profile of the strain. In particular, a reduction in the MICs of nine antibiotics was observed for hypermutable strain BST44, eight for NN83, seven for MF2, five for RP74, four for BT1, two for NN84 and one for SG2 (Table 1 ). The MICs for PAO1DmutS, used as a control, were reduced for all antibiotics tested when complemented with mutS (PAO1DmutS/mutS + ), indicating an absence of endogenous antibiotic resistance. On the other hand, the complementation with the MMR genes only partially restored wild-type antibiotic susceptibility in the mutator CF isolates, in agreement with previous work showing, through Etest susceptibility testing, that the documented resistance in clinical P. aeruginosa hypermutable strains is partially a consequence of both antibiotic exposure in vitro and endogenous resistance acquired during previous exposures in the CF patient's lung. 26 Costs versus benefits of P. aeruginosa hypermutable strains in the absence or presence of selection pressure in vitro
In a previous work we showed that in the absence of selection pressure P. aeruginosa hypermutable strains might be generally Alcalá -Franco et al.
disadvantaged when grown in the same environment with clonally related wild-type strains. 13 However, the hypermutable phenotype might reasonably advantage the P. aeruginosa strain in the presence of selection pressure such as an antimicrobial agent. To verify this hypothesis, pairs of clinical hypermutable/ wild-type clonally related P. aeruginosa strains, selected for their high propensity to develop antibiotic resistance after exposure in vitro, and the pair of reference strains PAO1DmutS/PAO1 were co-cultured at a starting ratio of 1 : 1 (Figure 1 ). The final ratio was determined after 24 h of growth in the presence or absence of two different antibiotics-streptomycin or ciprofloxacin. In the presence of streptomycin, the hypermutable strain outcompeted the wild-type strain(s) in the case of the pairs PAO1DmutS/PAO1 and BST44/BST2 (PAO1DmutS/PAO1 treated versus untreated CI 7.02 versus 0.33, P ¼ 0.0059; BST44/BST2 treated versus untreated CI 2.74 versus 0.75, P ¼0.0218). In the lineage NN, the presence of streptomycin determined a statistically significant increase in fitness for the hypermutable strain when compared with the absence of antibiotic, even if no outcompetition for the hypermutable strain was observed (NN83/ NN2 treated versus untreated CI 0.82 versus 0.10, P,0.0001).
In the presence of ciprofloxacin, the hypermutable significantly outcompeted the wild-type strain(s) in the reference and clinical pairs (PAO1DmutS/PAO1 treated versus untreated CI 1.91 versus 0.33, P ¼ 0.0013; BST44/BST2 treated versus untreated CI 20.63 versus 0.75, P¼ 0.015; NN83/NN2 1.51 versus 0.10, P ¼0.025).
Virulence of hypermutable P. aeruginosa strains in the absence or presence of selection pressure in a murine model of chronic infection
We previously demonstrated that the P. aeruginosa hypermutable strains are generally disadvantaged and less efficient in colonizing the murine airways when compared with wild-type under conditions of infection similar to those provided by the CF mucus. 13 To assess the virulence of a mixed population of P. aeruginosa hypermutable and wild-type strains during the course of chronic airways infection under selection pressure, competition experiments between reference PAO1DmutS/PAO1 and clinical BST44/BST2 pairs of hypermutable/wild-type strains were performed in the agar beads murine model ( Figure 2 and Table 2 ). After treatment with streptomycin or ciprofloxacin for 14 days, mortality, chronic infection, and the total population size of the bacteria present in lung samples were measured. Antibiotic treatment significantly reduced the mortality of mice infected with PAO1DmutS/PAO1 compared with placebo (streptomycin or ciprofloxacin treated 0% versus untreated 27%; x 2 , P ¼ 0.03), while the percentage of mice with chronic infection after 14 days was no different after treatment. The total cfu/ lung was unchanged when we compared untreated or antibiotictreated mice, indicating the therapeutic failure to eradicate chronic infection under these experimental conditions. However, under streptomycin or ciprofloxacin treatment the PAO1DmutS population outcompeted the wild-type population, while in the absence of antibiotic treatment the results were the opposite (PAO1DmutS/PAO1 treated versus untreated CI 2.83 and 1.38 for streptomycin and ciprofloxacin, respectively, versus 0.003; t-test, P ¼ 0.011). As shown in Figure 2 , the P. aeruginosa clinical lineage BST followed the laboratory strain and the ratio of BST44 hypermutable to BST2 wild-type strains recovered from treated mice increased when compared with the absence of streptomycin or ciprofloxacin (BST44/BST2 untreated versus treated CI 0.17 versus 1.26 or 2.90 for Pathogenicity of P. aeruginosa hypermutable strains 965 JAC streptomycin or ciprofloxacin, respectively; t-test, P,0.02). In addition, antibiotic treatment increased the percentage of mice infected with BST44/BST2, a figure that was significant in the case of streptomycin (streptomycin treated 67% versus untreated 27%; x 2 , P ¼ 0.03). Mortality was lower for mice infected with BST44/BST2 and treated with antibiotic compared with untreated, but the differences did not reach statistical significance as in the case of P. aeruginosa reference strains.
Overall, these results show a positive selection of the P. aeruginosa hypermutable strain during long-term airway colonization of mice administered antibiotic treatment compared with untreated mice.
Histopathological lesions of P. aeruginosa chronic pneumonia in the absence or presence of antibiotic treatment
The histopathological analysis of mice infected with the pair of P. aeruginosa hypermutable/wild-type clinical strains BST44/ BST2 indicated that the severity of lesions in the lung was similar in untreated (Figure 3a) or antibiotic-treated mice (Figure 3b) . Bronchi of untreated mice or ciprofloxacin-treated mice were filled with agar beads containing bacterial macrocolonies (Figure 3c ) or single cells (Figure 3d ) surrounded by a massive neutrophilic infiltration with the parenchyma principally infiltrated by macrophages, lymphocytes and neutrophils. Immunofluorescence staining showed that the infected bronchi contained agar beads with P. aeruginosa macrocolonies for untreated mice (Figure 3e ), while single bacterial cells (Figure 3g) were present in the beads of ciprofloxacin-treated mice, indicating that the 14 days of antibiotic treatment had affected the bacterial growth in the beads. In addition, compared with the mice treated with ciprofloxacin, the infected bronchi of untreated mice contained fewer and smaller agar beads, which were partially destroyed by extensive bacterial growth and degraded by neutrophils. The parenchyma showed persisting bacterial cells in untreated mice (Figure 3f ), but not in the ciprofloxacin-treated mice (Figure 3h ). Severe histopathological lesions were detected during chronic murine airway infection under antibiotic treatment. Indeed, antibiotic treatment did not lead to significant improvement in the lung pathology scores, though it encouraged selection of the hypermutable population. It can be assumed that multiple phenotypes of P. aeruginosa may also contribute to lung deterioration and disease progression in the CF lung habitat.
Discussion
One of the most striking characteristics of P. aeruginosa chronic lung infection in CF patients is the intense genetic adaptation and diversification of the bacterial population, leading to the co-existence of multiple phenotypes that are highly resistant to any chemotherapy treatment. 4, 27 Whole genome sequence analysis of P. aeruginosa sequential strains indicated rapid adaptation following colonization of the CF airways, followed by a long period (which also included the exacerbation period 28 ) with limited phenotypic change. 29 It has been shown that the accumulation of these so-called adaptive mutations is catalysed in part by the high prevalence of hypermutable strains in the CF setting that may emerge after the onset of colonization 30 or at a later stage. 12 If no hypermutators evolved, the point mutations remained amazingly low. 30 These observations are consistent with previous work on the CF mouse model showing that hypermutation favours long-term colonization. 31 Nevertheless, in Alcalá -Franco et al.
those experiments, adapted mutator lineages showed a reduced capacity for establishing new colonizations (i.e. reduced transmissibility), probably due to the accumulation of deleterious mutations for secondary enviroments. 29 Consistent with these findings, recent studies suggest that hypermutation might be counter-selected in late stages of microevolution of highly adapted and transmissible CF clones, such as clone C, DK2 or LES-1.
27 -29 Likewise, we have previously reported a decreased fitness and virulence of P. aeruginosa CF mutator populations in the absence of selection pressure when tested in competition experiments either in vitro or in a murine model of chronic infection. 13 However, in this study we showed that the disadvantage of hypermutability can become an advantage in the presence of selection pressure from the antimicrobial agent both in vitro and in vivo. During 2 weeks of administration of the antimicrobial agent to infected mice, the hypermutable PAO1DmutS strain outcompeted its isogenic wild-type PAO1 strain. These results confirmed and expanded previous findings in short-term evaluations (e.g. 3 days) of the therapeutic efficacy of antipseudomonal agents against the reference PAO1DmutS. 24, 32 The capacity of the hypermutable population to generate adaptive mutations faster than the wild-type enables bacteria to rapidly and efficiently cope with the drastic environmental changes encountered during selection pressure with the antimicrobial agent when grown in vitro and in infected murine lung.
Although the PAO1 strain has been highly informative, this laboratory-adapted strain, recovered from a wound infection more than five decades ago and sequenced many years ago, 18 does not represent the P. aeruginosa diversity observed in the natural population that belongs to the same species and that colonizes CF patients. 33 Therefore we tested additional pairs of clonally related P. aeruginosa hypermutable and wild-type strains. These P. aeruginosa strains belonged to CF patients Streptomycin and ciprofloxacin were introduced as selection pressure to the natural environment in which wild-type and hypermutable competition takes place. Streptomycin was chosen as an antibiotic not routinely used in the clinical situation, but a drug that can reach the lung tissue, 24, 34 and ciprofloxacin was chosen as a commonly used treatment in CF patients. When tested in vitro, the BST and NN lineages followed the PAO1 strain and show an advantage of the hypermutable strain when compared with the wild-type under streptomycin or ciprofloxacin antibiotic treatment. This advantage for the hypermutable strain did not occur in the absence of antibiotic treatment. Next, pairs of wild-type/hypermutable clinical strains were included in the agar beads and used to infect mice under antibiotic treatment. The cfu counts of clinical hypermutable strains in the lung were increased when compared with the wildtype strains in the process of establishing colonization under antibiotic pressure. Thus the advantage demonstrated by the P. aeruginosa hypermutable PAO1DmutS strain in vivo was also confirmed in the clinical strain. Severe histopathological lesions were detected during chronic murine airways infection under antibiotic treatment. Indeed, antibiotic treatment did not lead to significant improvement in the lung pathology scores while simultaneously selecting the hypermutable population. Obviously, multiple phenotypes of P. aeruginosa may also contribute to lung deterioration and disease progression in the CF lung habitat. Overall, these results showed that P. aeruginosa hypermutability, associated with an important biological cost in the absence of selection pressure, can be considered an advantage in the presence of selection pressure such as antibiotic treatments in the PAO1 laboratory strain and clinical strains. These findings emphasize the need for further studies to determine the generalizability of this mechanism with additional P. aeruginosa clonal lineages and to establish whether and how P. aeruginosa long-term chronic infection with hypermutable strains can determine the progression of lung disease.
